The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes

Cancer Research

Volumn 58, Issue 14, 1998, Pages 2969-2972

  Fleischhauer, Katharina ^a   Gattinoni, Luca ^a   Dalerba, Piero ^a   Lauvau, Grégoire ^b   Zanaria, Elena ^c   Dabovic, Branca ^c   Van Endert, Peter M ^b   Bordignon, Claudio ^a   Traversari, Catia ^a  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b INSERM   (France)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GENE PRODUCT; HLA A2 ANTIGEN; NUCLEOTIDE; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SEQUENCE HOMOLOGY;

ANTIGENS, NEOPLASM; HLA ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032528174     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Muscatelli, F., Walker, A. P., De Plaen, E., Stafford, A. N., and Monaco, A. P. Isolation and characterization of a MAGE gene family in the Xp21.3 region. Proc. Natl. Acad. Sci. USA, 92: 4987-4991, 1995.
2. Dabovic, B., Zanaria, E., Bardoni, B., Lisa, A., Bordignon, C., Russo, V., Matessi, C., Traversari, C., and Camerino, G. A family of rapidly evolving genes from the sex reversal critical region in Xp21. Mamm. Genome, 6: 571-580, 1995.
3. Boon, T., and Van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 193: 725-729, 1994.
4. Marchand, M., Weynants, P., Rankin, E., Arienti, F., Belli, F., Parmiani, G., Cascinelli, N., Bourlond, A., Vanwijck, R., Humblet, Y., Canon, J. L., Laurent, C., Naeyaert, J. M., Plagne, R., Deraemaeker, R., Knuth, A., Jaeger, E., Brasseur, F., Herman, J., Coulie, P. G., and Boon, T. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int. J. Cancer, 63: 883-885, 1995.
5. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide-or tumor lysatepulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
6. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
7. van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boël, P., De Smet, C., Traversari, C., Townsend, A., and Boon, T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol., 24: 3038-3043, 1994.
8. Kawakami, Y., Eliyahu, S., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
9. Cerundolo, V., Alexander, J., Anderson, K., Lamb, C., Cresswell, P., McMichael, A., Gotch, F., and Townsend, A. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature (Lond.), 345: 449-452, 1990.
10. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med., 179: 1109-1118, 1994.
11. Bennink, J. R., and Yewdell, J. W. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr. Top. Microbiol. Immunol., 163: 153-184, 1990.
12. Tanzarella, S., Fleischhauer, K., van Endert, P. M., Bordignon, C., and Traversari, C. Characterization of antigenic peptide epitopes by reverse immunology: induction of cytotoxic T lymphocytes specific for exogenous peptide only. Int. J. Cancer, 72: 912-915, 1997.
13. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., and Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176: 1453-1457, 1992.
14. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethé, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
15. Fleischhauer, K., Fruci, D., van Endert, P. M., Herman, J., Tanzarella, S., Wallny, H. J., Coulie, P. G., Bordignon, C., and Traversari, C. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int. J. Cancer, 68: 622-628, 1996.
16. Herman, J., van der Bruggen, P., Luescher, I. F., Mandruzzato, S., Romero, P., Thonnard, J., Fleischhauer, K., Boon, T., and Coulie, P. G. A peptide encoded by human gene MAGE-3 induces cytolytic T lymphocytes that recognizes tumor cells expressing MAGE-3, Immunogenetics, 43: 377-383, 1996.
17. Tussey, L. G., Rowland-Jones, S., Zheng, T. S., Androlewicz, M. J., Cresswell, P., Freilinger, J. A., and McMichael, A. J. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity, 3: 65-77, 1995.
18. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., and Sette, A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell, 74: 929-937, 1993.
19. Rammensee, H. G., Friede, T., and Stefanovic, S. MHC ligands and peptide motifs: first listing. Immunogenetics, 41: 178-228, 1995.
20. Valmori, D., Liénard.'D., Waanders, G., Rimoldi, D., Cerottini, J. C., and Romero, P. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res., 57: 735-741, 1997.
21. Meadows, L., Wang, W., den Haan, J. M. M., Blokland, E., Reinhardus, C., Drijfhout, J. W., Shabanowitz, J., Pierce, R., Agulnik, A. I., Bishop, C. E., Hunt, D. F., Goulmy, E., and Engelhard, V. H. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity, 6: 273-281, 1997.
22. Skipper, J. C. A., Hendrickson, R. C., Gulden, P. H., Brichard, V., Van Pel, A., Chen, Y., Shabanowitz, J., Woelfel, T., Slingluff, C. L., and Boon, T. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J. Exp. Med., 183: 527-534, 1996.
23. Imanishi, T., Akaza, T., Kimura, A., Tokunaga, K., and Gojobori, T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: K. Tsuji, M. Aizawa, and T. Sasazuki (eds.), HLA 1991, Vol. 1, pp. 1065-1169. Oxford, United Kingdom: Oxford University Press, 1992.